A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.

@article{Cohn2013ARP,
  title={A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.},
  author={Allen Lee Cohn and Josep Tabernero and Joan Maurel and Elżbieta Nowara and Javier M. Sastre and Benjamin Yen Seong Chuah and Mikhail V. Kopp and D. D. Sakaeva and Edith Peterson Mitchell and Sarita Dubey and Samuel Suzuki and Y J Hei and Francesco Galimi and Ian McCaffery and Yang Pan and Robert D. Loberg and Susan Cottrell and S-P Choo},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2013},
  volume={24 7},
  pages={1777-85}
}
BACKGROUND Targeted agents presently available for mutant KRAS metastatic colorectal cancer (mCRC) are bevacizumab and aflibercept. We evaluated the efficacy and safety of conatumumab (an agonistic monoclonal antibody against human death receptor 5) and ganitumab (a monoclonal antibody against the type 1 insulin-like growth factor receptor) combined with standard FOLFIRI chemotherapy as a second-line treatment in patients with mutant KRAS mCRC. PATIENTS AND METHODS Patients with mutant KRAS… CONTINUE READING
24 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 24 extracted citations

Similar Papers

Loading similar papers…